Implantable cardioverter defibrillators and cardiac resynchronisation therapy

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Implantable cardioverter defibrillators and cardiac resynchronisation therapy (CRT) are standard treatments for heart failure.
• Evidence supports CRT benefits in symptomatic (NYHA class III) and mildly symptomatic (NYHA class II) heart failure patients.

Purpose of the Study:

• To critically assess landmark randomized clinical trials (REVERSE, MADIT-CRT, RAFT) on CRT.
• To discuss emerging indications for CRT, including specific patient subgroups and optimization.

Main Methods:

• Review and critical assessment of landmark randomized clinical trials.
• Discussion of evidence for expanded CRT indications and patient response.

Main Results:

• CRT is recommended for both NYHA class II and III heart failure patients.
• Evidence supports exploring CRT in patients with mildly reduced LVEF and narrow QRS.

Conclusions:

• CRT is a cornerstone in heart failure management for a broader patient population.
• Further research and optimization are crucial for non-responders and improving CRT efficacy.